SCHEMBL14929347

SCHEMBL14929347

CC(=O)Nc1ccn([C@@H]2O[C@H](CO)C(O)[C@@H]2O)c(=O)n1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.65
MTOR P42345 2/20 0.65
THRB P10828 1/20 0.65
MDM2 Q00987 1/20 0.65
NCOA1 Q15788 1/20 0.65
NCOA3 Q9Y6Q9 1/20 0.65
MAPT P10636 1/20 0.55
CDA P32320 1/20 0.55
ALDH1A1 P00352 2/20 0.52
GMNN O75496 1/20 0.52
TP53 P04637 1/20 0.52
NFKB1 P19838 1/20 0.52
DNMT1 P26358 1/20 0.52
THPO P40225 1/20 0.52
HTT P42858 1/20 0.52
RAB9A P51151 1/20 0.52
BLM P54132 1/20 0.52
HBB P68871 1/20 0.52
PMP22 Q01453 1/20 0.52
SLC28A1 O00337 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20967857 1.00 LMNA (0.65) LMNAMTORTHRBMDM2NCOA1
SCHEMBL20628772 1.00 LMNA (0.65) LMNAMTORTHRBMDM2NCOA1
SCHEMBL14946394 1.00 LMNA (0.65) LMNAMTORTHRBMDM2NCOA1
SCHEMBL20459954 1.00 LMNA (0.65) LMNAMTORTHRBMDM2NCOA1
SCHEMBL453448 1.00 LMNA (0.65) LMNAMTORTHRBMDM2NCOA1
SCHEMBL6397305 1.00 LMNA (0.65) LMNAMTORTHRBMDM2NCOA1
SCHEMBL453447 1.00 LMNA (0.65) LMNAMTORTHRBMDM2NCOA1
Phosphoric Acid SCHEMBL15668496 0.96 LMNA (0.60) LMNAMTORTHRBMDM2NCOA1
Cytidine SCHEMBL15054404 0.94 LMNA (0.77) LMNAMTORTHRBMDM2NCOA1
SCHEMBL27056643 0.92 LMNA (0.55) LMNAMTORTHRBMDM2NCOA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3229026-A1 BIOMARKERS FOR THE DIAGNOSIS OF INFLAMMATION-RELATED DISEASES UNIVERSITE DE BORDEAUX (FR) 2017-10-11 EP disclosed
US-20170056528-A1 MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF MODERNATX, INC. 2017-03-02 US disclosed
US-20170056528-A1 MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF MODERNATX, INC. 2017-03-02 US disclosed
US-9428535-B2 Modified nucleosides, nucleotides, and nucleic acids, and uses thereof MODERNA THERAPEUTICS, INC. (US) 2016-08-30 US disclosed
US-9428535-B2 Modified nucleosides, nucleotides, and nucleic acids, and uses thereof MODERNA THERAPEUTICS, INC. (US) 2016-08-30 US disclosed
US-20130123481-A1 MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF modeRNA Therapeutics (US) 2013-05-16 US disclosed
US-20130115272-A1 MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF modeRNA Therapeutics (US) 2013-05-09 US disclosed
US-20130115272-A1 MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF modeRNA Therapeutics (US) 2013-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130123481-A1 MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF ADAR, NT5C3B, NSUN2 LMNA 585/4885MTOR 4256/4885THRB 3988/4885
US-20170056528-A1 MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF ADAR, NT5C3B, NSUN2 LMNA 585/4885MTOR 4256/4885THRB 3988/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.